Successful treatment of acute promyelocytic leukemia (APL) has identified several novel approaches to induce leukemic cell differentiation and selective apoptosis by overcoming the sitespecific transcriptional repression by dominant fusion leukemogenic proteins characteristic of APL and other forms of acute myelogenous leukemia (AML). These therapeutic approaches include the use of site-specific ligands, receptors and cytokines, disruption of dominant fusion leukemogenic proteins, chromatin remodeling and combining the above with cytotoxic chemotherapy. With the exception of cytotoxic chemotherapy, the above therapeutic strategies do not significantly affect normal hematopoiesis and their combinations have been shown to be synergistic in inducing myeloid differentiation and apoptosis in several AML cell lines and in patients with APL. These approaches are, in general, non-cross resistant and should be well tolerated particularly in elderly patients with AML. Clinical studies which include biologic end points for differentiation induction, histone acetylation and selective apoptosis are presently in development to evaluate these strategies in the treatment of AML. Leukemia (2000) 14, 491-496.
Introduction
Clinically effective differentiation therapy in acute myelogenous leukemia (AML) has been demonstrated only in the M3 t(15;17) acute promyelocytic leukemia (APL). In APL, all-trans retinoic acid (ATRA) induces leukemic cell terminal differentiation and hematologic remission in 90% of patients. [1] [2] [3] This remarkable clinical observation was initially based on the observation that retinoids induced terminal cell division in established leukemia cell lines. 4 This biological observation and treatment of APL was made prior to the knowledge that dominant negative repression of RAR␣ nuclear receptor function by PML RAR␣, the product of t (15;17) , was the molecular basis for leukemic transformation in APL. 5, 6 The understanding of the molecular basis of the myeloid transformation to APL resulting from the PML RAR␣ protein has brought forward a model for the development of novel strategies for overcoming the site-specific transcriptional repression involved in the transformation (Figure 1 ). 7 RAR␣ in heterodimeric form with RXR is associated with an NCoR/Sin3A/Histone Deacetylase (HDAC1) corepressor complex. 8 RAR␣ is maintained in a repressed state when associated with the corepressor as a result of deacetylation of histone tails within the nucleosome resulting in less accessibility to basal transcription factors. During normal myeloid differentiation (Figure 1a ), physiologic concentrations of ATRA induce confirmational changes in the RAR␣ causing dissociation of the corepressor complex with subsequent recruitment of an SRC co-activator complex with intrinsic histone acetyltransferase activity. The subsequent acetylation of histone tails disrupts the tightly packed and repressed chromatin structure allowing for access to the basal transcription factors and transcriptional activation. Site-specific transcriptional repression by PML RAR␣ protein results from inefficient dissociation of the N-CoR repressor complex from the fusion protein at physiologic concentrations of ATRA (Figure 1b) . Pharmacologic amounts of ATRA (1M) are required to dissociate the N-CoR corepressor complex and initiate a chromatin structure amenable to transcriptional activation. 7, 9, 10 Other forms of acute leukemias are associated with translations which encode fusion leukemogenic proteins which bind repression complexes and manifest their presence by site-specific transcriptional repression (Table 1) . Lessons learned from APL in the laboratory which have translated to the clinic serve the basis for the extension of these therapeutic strategies to overcome site-specific transcriptional repressions in other forms of leukemia (Table 2 ). These therapeutic approaches will be reviewed in this report.
Site-specific ligands and receptors
Site-specific transcriptional repression corrected by a specific ligand is best demonstrated by ATRA as a ligand for the RAR␣ nuclear receptor which plays an important role in myeloid differentiation and is disrupted in APL cells. Thus far, a similar site-specific ligand has not been demonstrated to be capable of correcting transcriptional repression in other forms of AML. However, in vitro studies in non-APL leukemic cell lines have demonstrated that retinoids induce differentiation perhaps by pharmacologically upregulating normal RAR␣ signalling pathways and when given in combination with low-dose chemotherapeutic agents such as cytosine arabinoside, cytokines such as granulocyte colony-stimulating factor (G-CSF) may induce synergistic differentiation and apoptosis. 11, 12 The exposure of APL cells and other AML cells to retinoic acid results in the induction of the expression of G-CSF receptor which may render these cells more responsive to G-CSF induced differentiation and apoptosis. The induction of surface differentiation antigens by retinoids without significant evidence for morphologic differentiation may render leukemic cells susceptible to antibody targetted therapies. The development of vitamin D3 analogs which induce differentiation and apoptosis in various leukemia cell lines, but not hypercalcemia in animal models, suggest that these agents may be important as future treatments in various forms of AML. 13 Interferon alpha, perhaps by down-regulation of BCR ab1 message, 14 has been shown to be effective as a treatment in chronic myelogenous leukemia but not in AML. Interferon gamma but not interferon alpha synergizes with retinoic acid to induce retinoic acid responsive genes and differentiation in APL cells (Figure 2 ). Similar studies are needed in non-M3 acute leukemias in order to determine whether these synergisms also occur. 
Disruption of dominant fusion leukemogenic proteins
Site-specific transcriptional repression by fusion leukemogenic proteins serve as targets for therapy. ATRA in addition to dissociating transcriptional co-repressors from PML RAR␣ and the wild-type RAR␣ nuclear receptor, initiates degradation of PML RAR by a specific proteolytic pathway which plays an important role in differentiation induction of APL cells. 15 Arsenic trioxide (As 2 O 3 ), an agent shown to predictably induce clinical remission in APL causes both apoptosis and differentiation induction in vitro and in vivo. 16 As 2 O 3 also targets PML RAR␣ for degradation but by a pathway other than ATRA. 17 ATRA is synergistic with As 2 O 3 to induce differentiation particularly in ATRA-resistant APL cells. Bcl-2 is also degraded in some As 2 O 3 and ATRA-treated non-APL leukemic cell lines in vitro and in vivo and this may render these cells sensitive to cytotoxic agent-induced apoptosis. 16 Whether As 2 O 3 can degrade other fusion proteins which induce site-specific transcriptional repression in AML remains to be determined. The use of targeted anti-sense molecules to block the expression of leukemogenic fusion proteins which induce site-specific transcription repression offers another means of therapeutic intervention.
Chromatin remodelling as a strategy for overcoming transcriptional repression
Differentiation can be effectively induced by various chemical inducers in several AML cell lines. Butyrates, such as sodium butyrate and phenylbutyrate (PB) induce differentiation in non-APL cell lines such as U937 and HL-60 cells and are synergistic with ATRA. 7, 18 The synergism has been demonstrated in vitro (Table 3 ) and in vivo in APL cells 19 and may be related to the ability of butyrates to inhibit HDAC and increase acetylation of histones. As discussed above (Figure 1) , increasing histone acetylation results in a physical change in histone tails that allow for opening of nucleosomes which allows for more effective binding of cis-acting transcription factors and initiation of transcription. This is an increasingly complex process and involves several forms of HDAC which tend to sup- press transcription by binding to specific transcription factor complexes. For example, the ATRA differentiation resistant t(11;17) APL 20 is explained by the binding of the fusion protein PLZF RAR to N-CoR, a transcriptional repressor which is part of a complex that contains HDAC activity (Figure 1c ). This binding suppresses transcription by two mechanisms, ie blocking the release of N-CoR from the RAR␣ nuclear receptor even in the presence of pharmacologic amounts of ATRA and also the maintenance of the repressed state due to sustained activity of HDAC. Despite this defect, differentiation and clinical remission was successfully achieved in one patient treated Leukemia with ATRA in combination with G-CSF. 21 In another patient with APL, with known resistance to ATRA and all forms of cytotoxic chemotherapy, PB treatment with ATRA-induced differentiation, increased histone acetylation in the patient's myeloid cells and clinical remission. 19 Leukemic transformation in t(8;21) AML may relate to the binding of a repressor with HDAC activity by the AML, ETO fusion protein resulting in site-specific transcriptional repression. 22 Further transcriptional repression may result from binding of PLZF to ETO thus recruiting additional HDAC. increased histone acetylation and induced differentiation. 23 PB has also been shown to have clinical activity in patients with myelodysplastic syndrome and AML and is synergistic to induce differentiation and apoptosis in various leukemia cells lines when combined with G-CSF and dexamethasone, particularly in t(8;21) AML cells. 23 Chemical differentiation inducers such as butyrates and hexamethylene bisacetamide (HMBA) and its derivatives characteristically induce a differentiation program which is associated with induction of G1 cell cycle arrest which is partially explained by the induction of p21 WAF1 and Rb hypophosphorylation. 24 Clinically, these agents have been used with only modest success which may be explained in part by the high concentrations (mM) necessary for the induction of differentiation. 25 Although these drugs even at mM concentrations, appear to be minimally toxic, the logistics of delivering such a large quantity of drug for long periods of time diminishes their clinical utility. Newer chemical inducers derived from HMBA effectively induce differentiation in leukemia cells at 10 M and apoptosis at slightly higher concentrations. 26 These HMBA derivatives unlike the parental HMBA inhibit HDAC activity and increase histone acetylation in leukemic cells. 26 We have discovered novel chemical differentiation inducers, which at 5 M synergize ATRA induction of differentiation in NB4 cells without significant toxicity and overcome transcriptional repression by PML RAR␣. One compound, NSC 656243 at 5 M is a stronger inducer of differentiation in t(8;21) Kazumi cells than PB (Figure 3) . Unlike the HMBA derivatives these compounds are not inhibitors of HDAC and do not change histone acetylation. Future goals in the development of chemical differentiation inducers include identification of drugs that selectively inhibit a specific form of HDAC and a mechanism for obtaining a localized change in histone acetylation so that site-specific transcriptional repression can be overcome without inducing multiple repressed genes. Combining drugs to modulate histone acetylation with drugs such as azacytadine to decrease DNA methylation 27 and enhance gene expression may be useful in overcoming the site-specific transcriptional repression associated with certain forms of AML.
In vitro treatment of Kazumi t(8;21) AML cells with PB

Combination cytotoxic-differentiation therapy
Differentiation of leukemia cells, as measured by morphologic changes, ie Auer rods in segmented neutrophils (PMN) obtained from bone marrow has been observed in patients undergoing cytotoxic chemotherapy treatment for AML. Similarly, the in vivo incorporation of bromodeoxyuridine into PMN in some patients with AML prior to chemotherapy also supports differentiation of leukemia cells. Interestingly, this was associated with a more favorable response to cytotoxic chemotherapy and a more durable clinical remission suggesting a role for differentiation during chemotherapy-induced remission. APL or the t(8;21) AML1-ETO, which have more favorable responses to chemotherapy, are associated with evidence for in vitro and in vivo differentiation induction.
Preclinical studies have demonstrated that the sequential treatment of leukemia cells with cytotoxic agents followed by differentiation agents resulted in synergistic induction of differentiation and apoptosis. More specifically, pretreating t(15;17) NB4 cells, HL-60 cells (non-APL leukemia) and primary culture of AML cells with cytotoxic agents prior to exposure to ATRA resulted in synergistic differentiation and apoptosis. 28 Similarly, murine erythroleukemia cells (MEL) demonstrated enhanced differentiation and apoptosis when pretreated with cytotoxic agents and followed by the differentiation inducer HMBA. 29 This synergism was not found in normal murine progenitor cells as measured by colony-forming assays and suggests that the combination cytotoxic differentiation synergy was selective for leukemia cells. 30 This selective synergism may relate to the observation that certain cytotoxic agents can arrest leukemic cells in the G1 phase of the cell cycle, enhance the induction of p21 WAF1 message and protein which make leukemia cells more responsive to differentiation induction by chemical differentiation inducers. 31 Moreover, DNA repair processes are rapidly downregulated during differentiation induction of leukemic cells and consequently intracellular levels of previously administered cytotoxic agents are more effective in producing leukemia cell death by apoptosis. Recent reports support these pre-clinical findings since combining cytotoxic chemotherapy with ATRA in the treatment of APL has resulted in a higher incidence with more durable clinical remissions as compared to either treatment alone. 32 In summary, basic and translational research in APL have demonstrated several novel approaches to overcome the sitespecific transcriptional repression characteristic of other forms of AML. The mouse model produced by the knock-in of PML RAR␣ which creates a clinical entity similar to APL has allowed for the testing of several of these novel approaches. 33 As we develop similar animal models in other forms of AML it is predicted that progress will be made at a more rapid pace. Clinical observations made in APL have demonstrated that specific-ligand induction of differentiation can be enhanced by cytotoxic chemotherapy or in combination with other agents such as cytokines and agents that increase histone acetylation. Clinical protocols to test these principles in other forms of AML, particularly in the elderly patients or in secondary leukemia, are presently in development and their efficacy will be established not only by clinical response but by the ability to measure biologic end points such as differentiation induction, changes in histone acetylation and selective apoptosis. Figure 3 t(8;21) Kazumi cells were treated with phenylbutyrate (PB) (1 mM), HMBA (2 mM) and NSC 656243 (5 M) for 7 days. Differentiation was measured by the expression of CD11b. The data demonstrate that NSC 656243 is a more powerful differentiation inducer in these cells.
